TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:37
ARDELYX INC. ( ARDX ) https://www.ardelyx.com
4.81USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-25.08%
ARDX
SPY
32.66%
ARDX
366.99%
SPY
108.59%
-35.44%
ARDX
SPY
302.52%
-74.72%
ARDX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1080.47
893.86
4.42
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-14.89
4.29
6.83
-3.92
0.00
-28.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
2.27
85.74
-10.06
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.9264
-29.79
-18.21
0.98
Other Earnings and Cash Flow Stats:
ARDELYX INC. ( ARDX ) Net Income TTM ($MM) is -72.58
ARDELYX INC. ( ARDX ) Operating Income TTM ($MM) is -64.06
ARDELYX INC. ( ARDX ) Owners' Earnings Annual ($MM) is -89.94
ARDELYX INC. ( ARDX ) Current Price to Owners' Earnings ratio is -16.09
ARDELYX INC. ( ARDX ) EBITDA TTM ($MM) is -62.15
ARDELYX INC. ( ARDX ) EBITDA Margin is -10.06%
Capital Allocation:
ARDELYX INC. ( ARDX ) has paid 0.00 dividends per share and bought back -8.017064 million shares in the past 12 months
ARDELYX INC. ( ARDX ) has reduced its debt by 34.973 million USD in the last 12 months
Capital Structure:
ARDELYX INC. ( ARDX ) Interest-bearing Debt ($MM) as of last quarter is 3
ARDELYX INC. ( ARDX ) Annual Working Capital Investments ($MM) are 1
ARDELYX INC. ( ARDX ) Book Value ($MM) as of last quarter is 158
ARDELYX INC. ( ARDX ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
ARDELYX INC. ( ARDX ) has 47 million in cash on hand as of last quarter
ARDELYX INC. ( ARDX ) has 70 million of liabilities due within 12 months, and long term debt 100 as of last quarter
ARDELYX INC. ( ARDX ) has 235 common shares outstanding as of last quarter
ARDELYX INC. ( ARDX ) has 0 million USD of preferred stock value
Academic Scores:
ARDELYX INC. ( ARDX ) Altman Z-Score is 0.96 as of last quarter
ARDELYX INC. ( ARDX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ARDELYX INC. ( ARDX ) largest shareholder is owning shares at 0.00 ($MM) value
MOTT DAVID M(an insider) Bought 213300 shares of ARDELYX INC. ( ARDX ) for the amount of $996580.26 on 2024-12-19
1.58% of ARDELYX INC. ( ARDX ) is held by insiders, and 61.86% is held by institutions
ARDELYX INC. ( ARDX ) went public on 2014-06-19
Other ARDELYX INC. ( ARDX ) financial metrics:
FCF:-63.80
Unlevered Free Cash Flow:63.13
EPS:-0.01
Operating Margin:2.27
Gross Profit Margin:85.74
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2.04
Beta:0.98
Buffet's Owners Earnings:-89.94
Price to Owner's Earnings:-16.09
About ARDELYX INC. ( ARDX ) :
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.